Platelet-rich Plasma Improves Hair Loss, Scars, and More

Article

A meta-analysis of studies found that treatment with platelet-rich plasma improves androgenetic alopecia, scarring, and other dermatologic conditions.

Jeffrey Rapaport, MD, FAAD

Jeffrey Rapaport, MD, FAAD

Investigators conducting a literature review found that platelet-rich plasma is a successful treatment for various dermatologic conditions, including androgenetic alopecia (AGA), scars, nasolabial folds, and photoaging.

The research, which was presented at the 2019 Annual Meeting of the American Academy of Dermatology (AAD) in Washington, DC, was a meta-analysis of studies found in PubMed about the efficacy of treatment with platelet-rich plasma (PRP).

“The anti-inflammatory and multi-factorial capabilities of PRP could be advantageous in the treatment of a wide array of dermatology-based applications,” wrote Jeffrey Rapaport, MD, FAAD, a board-certified dermatologist in private practice in New Jersey, and colleagues.

Rapaport specifically addressed the potential for PRP to treat hair loss.

“A general body of evidence has recently emerged demonstrating a positive response from PRP treatments,” said Rapaport in a statement. “With consensus forming around treatment protocols, studies are indicating that PRP is a safe, effective hair loss treatment that has the potential to greatly improve the quality of life of millions of people.”

The meta-analysis gathered a total of 58 studies that fit inclusion criteria. Of those, 23 examined androgenetic alopecia (AGA), and 3 covered alopecia areata (AA). There were also 8 acne studies, 14 facial skin studies, 1 facial burn study, and 9 facial procedure studies. No studies were found that dealt with cicatricial alopecia (CA).

The investigators found that 3 sessions of platelet-rich plasma treatment spaced every 4 weeks successfully treated androgenetic alopecia compared to placebo, as measured by the change in hair density (hair/cm2). The mean difference in hair density was 25.61 (95% Confidence Interval, 4.45 to 46.77; P = .02).

The study also found that 2 to 4 sessions of platelet-rich plasma treatment significantly improved scar severity when used in addition to aesthetic therapies including micro-needling and erbium fractional lasers.

Platelet-rich plasma treatment was found to significantly improve the severity of nasolabial folds, signs of photoaging, and color homogeneity. Finally, adding platelet-rich plasma to lipofilling procedures significantly decreased the number of recovery days patients required.

Still, while platelet-rich plasma is a promising treatment for various conditions, Rapaport stressed the need for certified dermatologists to determine which patients are good candidates to benefit from PRP treatment.

“Since PRP therapy has taken off, there have been a lot of non-dermatologists performing this procedure,” Rapaport says. “Only board-certified dermatologists have the medical training to identify if you are a good candidate, because this treatment will not work for everyone who experiences hair loss.”

The investigators also pointed to the need for further research on PRP therapy, particularly for acne scarring and hair loss.

“With further investigation using randomized, controlled studies, a standardized PRP protocol for aesthetic conditions such as acne scarring and hair loss can be created,” they wrote.

The abstract, “The Efficacy of Platelet-Rich Plasma (PRP) in Dermatology,” was presented as a poster at the AAD Annual Meeting on Friday, March 1, 2019.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.